Background Locoregionally advanced, recurrent, and metastatic squamous cell carcinomas
of the head and neck (SCCHN) remain difficult to treat disease entities, in which systemic …

Importance There remains an unmet need to improve clinical outcomes in patients with
recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN) …

6009 Background: Patients (pts) with R/M SCCHN have poor prognosis, and median OS for
pts with platinum-refractory disease is≤ 6 mo. We investigated if nivo, a fully human IgG4 …

Background The standard of care for first-line treatment of recurrent and/or metastatic
squamous cell carcinoma of the head and neck (R/M SCCHN) is combination treatment with …

Background Results from a phase 2 trial of the TPEx chemotherapy regimen (docetaxel–
platinum–cetuximab) showed promising results, with a median overall survival of 14· 0 …

Purpose This was an open, randomized, multicenter, phase I/II study to investigate the safety
and tolerability of cetuximab in the first-line treatment of recurrent/metastatic squamous cell …

Abstract Learning Objectives Compare survival outcomes among patients with SCCHN
treated with a platinum/5‐FU regimen with and without cetuximab. Compare adverse event …

Objectives Many patients with squamous cell carcinoma of the head and neck (SCCHN)
are≥ 65 years old; comorbidities and other age-related factors may affect their ability to …

Head and neck squamous cell carcinoma (HNSCC) is the sixth most common cause of
cancer death worldwide. Its treatment is complex and evolving. In general, early-stage …

Simple Summary To improve overall survival (OS), we evaluated a combination of
cetuximab and nivolumab for toxicity and efficacy in patients with incurable recurrent and/or …